PamGene's microarray diagnostics shows promise:
This article was originally published in Clinica
Executive Summary
PamGene International, of `s-Hertogenbosch, the Netherlands, says that preliminary results from research to develop rapid microarray diagnostics for tuberculosis identification and drug resistance monitoring are promising. The firm is developing the microarray platform, PamChip, with KIT Biomedical Research, the business unit of KIT at Amsterdam's Royal Tropical Institute. It claims that according to its research, the technology could represent the "world's fastest microarray". The rapid technology, it says, was achieved by pulsing the target through a porous substrate of different probes for mycobacteria species identification.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.